Humana Expands Medicare Advantage Coverage for CVRx’s Barostim Therapy — CVRx, Inc.

Event summary

Humana issued a Medicare Advantage coverage policy for CVRx’s Barostim therapy, effective May 1, 2026.
The policy covers patients meeting FDA-approved indications and those enrolled in the BENEFIT-HF trial.
Humana provides coverage to approximately 5.2 million Medicare Advantage members across 46 states.
This follows two other positive reimbursement developments for Barostim in 2026: Category I CPT codes and CMS Category B IDE coverage.

The big picture

Humana’s coverage policy for Barostim therapy marks a significant milestone in CVRx’s efforts to expand access to its neuromodulation solution for heart failure patients. This development aligns with broader industry trends toward value-based care and payer education on innovative medical technologies. The policy’s validation of CVRx’s commercial strategy could enhance its negotiating power with other payers, potentially accelerating adoption of Barostim in the Medicare Advantage market.

What we're watching

Payer Adoption: Whether Humana’s policy will accelerate discussions with other regional and national payers, expanding Barostim’s market reach.
Clinical Validation: The pace at which the BENEFIT-HF trial results will influence broader reimbursement and adoption of Barostim therapy.
Competitive Dynamics: How CVRx’s reimbursement strategy will position it against other neuromodulation solutions in the cardiovascular disease space.